– GTB-5550, which harbors wild-type IL-15, and BiKE display broad activity against B7-H3-expressing tumors – Compared to monomeric IL-15, GTB-5550 shows CD16-dependent metabolic activation of NK cells BEVERLY HILLS, Calif., – GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on the...
Latest News
Gwangju, South Korea – Metabolic dysfunction-associated steatotic liver disease (MASLD) is a burgeoning global health concern, posing a significant threat to public health and escalating the burden on healthcare resources. Characterized by the accumulation of fat in the liver, MASLD increases the risk of progressing to more severe conditions such...
TAMPA, Fla. — Multiple myeloma remains challenging to treat. New therapeutic advances have improved outcomes, but selecting the right treatment for a patient can be complex because the disease can vary drastically from person to person. In a new article published in the Journal of Clinical Oncology, Moffitt Cancer Center...
TAMPA, Fla. — Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone. Roughly 90% of men with advanced prostate cancer will develop...
OTTAWA, ON – CSL Behring Canada announced that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), is now available in all of Canada. HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients.1 HAE patients have absent or low levels of endogenous or...
Jackson Center, PA – Halberd Corporation (OTC-PINK: “HALB“) received notification from the Ference Law Firm in Pittsburgh of a Notice of Allowance, by the US Patent Office, for the treatment of Cockayne Syndrome. Cockayne Syndrome is a fatal autosomal recessive neurodegenerative disorder which causes premature aging and severely impaired development...
LEHI, Utah — Halia Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced six poster presentations and one oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition taking place in Orlando, Florida, from December 6-9, 2025. Ofirnoflast is a novel, oral, allosteric NEK7 inhibitor designed...
SAN DIEGO, CA — Halozyme Therapeutics, Inc., today announced that argenx received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) injection co-formulated with Halozyme’s ENHANZE® drug delivery technology for subcutaneous (SC) use for the treatment of adult patients with generalized myasthenia gravis...
SAN DIEGO, Calif. — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Takeda received European Commission (EC) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme’s ENHANZE® drug delivery technology as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilization with intravenous...
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China – Harbour BioMed (“HBM”, HKEX: 02142) today announced positive topline results from its Phase 2 proof-of-concept clinical trial of batoclimab (HBM9161) in Chinese generalized myasthenia gravis (gMG) patients. Data received from the Phase 2 Study, as the first clinical evidence of anti-FcRn therapies in Chinese patients, showed...